2016
Titularprofessor der Universität Basel

2013
Stellvertretender Chefarzt Medizinische Onkologie 

2010
Leitender Arzt Med. Onkologie, St. Claraspital Basel

2008
Oberarzt Med. Onkologie, St. Claraspital Basel

2008
Habilitation in Medizinischer Onkologie, Universität Basel  

2007 - 2008
College-M-Kurs: Management im Gesundheitswesen «Managen heute»

2006 - 2008
Oberarzt Med. Onkologie und Vertreter der Med. Onkologie im Behandlungszentrum Lunge, Universitätsspital Basel

Seit 2006
Departement Forschung Universitätsspital Basel

2004 - 2006
Postdoctoral Fellowship, Departement of Biochemistry, School of Medicine, Stanford University, California

2004
FMH Medizinische Onkologie

2002 - 2003
Assistenzarzt Medizinische Onkologie Universitätsspital Basel

2002
Stellvertreter Oberarzt Innere Medizin Universitätsspital Basel

2002
FMH Innere Medizin

2000 - 2003
Forschung Med. Onkologie und Dep. Universitätsspital Basel

2000 - 2001
Assistenzarzt Innere Medizin Universitätsspital Basel (inkl. IPS, Onkologie, Hämatologie)

1998
PhD, summa cum laude, Universität Basel Switzerland, «Comparative gene expression analysis of a v-H-ras induced IL-3 autocrine tumor model»

1998 - 2000
Assistenzarzt Innere Medizin Kantonsspital Bruderholz (inkl. IPS und Notfallstation)

1996
USMLE: ECFMG certificate

1996
MD, Universität Basel «Application of Differential Display PCR to compare precursors and v-H-ras transformed tumor cell lines of the PB-3c tumor model»

1994 - 1998
Forschungsassistent Inst. für med. Mikrobiologie Universität Basel

1994
Eidgenössisches Staatsexamen, Universität Basel

1992 - 1993
European Master of Clinical Research Basic Course, Universitäten Basel, Freiburg und Strassbourg

1988 - 1994
Medizinstudium Universität Basel

• Schweizerische Gesellschaft für Medizinische Onkologie (SGMO)
• Schweizerische Gesellschaft für Allgemeine Innere Medizin (SGAIM)
• Swiss MD-PhD Association (SMPA)

• Appius H, Hafer J, Harms W, Bolli M, Buess: Reproducibility of the CROSS-Trial Results in the Multimodal Treatment of Esophageal Cancer in Daily Practice: A Single Center Retrospective Observational Study. M. J Oncol. 8955720. Rösch M, Bieg C, Savic S, Buess M: Androgen Deprivation Therapy for Intracranial Metastasis of a Salivary Duct Carcinoma: Case Report. Case Rep Oncol: 16 (1): 109–115.
• Del Rio J, Buess M: Outcome of Hospitalized Cancer Patients with Hypernatremia: A Retrospective Case-Control Study. Curr Oncol. 29(11): 8814-8824 (2022).
• Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, Früh M, Joerger M, Lardinois D, Gelpke H, Mauti LA, Britschgi C, Weder W, Peters S, Mark M, Cathomas R, Ochsenbein AF, Janthur WD, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Godar G, Rusterholz C, Gonzalez M, Pless M: Swiss Group for Clinical Cancer Research (SAKK). SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. 2021: J Clin Oncol. 39(26):2872–2880.
• Alborelli I, Leonards K, Rothschild SI, Leuenberger LP, Savic Prince S, Mertz KD, Poechtrager S, Buess M, Zippelius A, Läubli H, Haegele J, Tolnay M, Bubendorf L, Quagliata L, Jermann P. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer. J Pathol. 2020 Jan;250(1):19-29. doi: 10.1002/path.5344. Epub 2019 Oct 24. PMID: 31471895; PMCID: PMC6972587.
• Wallrabenstein T, Del Rio J, Templeton AJ, Buess M (2020) Much has changed in the last decade except overall survival: A Swiss single center analysis of treatment and survival in patients with stage IV non-small cell lung cancer. PLoS ONE 15(5): e0233768. https://doi.org/10.1371/journal.pone.0233768
• Ferraro DA, Patella F, Zanivan S, Donato C, Aceto N, Giannotta M, Dejana E, Diepenbruck M, Christofori G, Buess M; Endothelial cell-derived nidogen-1 inhibits migration of SK-BR-3 breast cancer cells. BMC Cancer. 2019 Apr 4; 19(1): 312.
• Rajski M., Saaf A., Buess M.: BMP2 response pattern in human lung fibroblasts predicts outcome in lung adenocarcinomas. BMC Med Genomics. Apr 2015: 29; 8:16: 1–12
• Harms W., Geretschläger A., Cescato C., Buess M., Köberle D., Asadpour B.: Current Treatment of Isolated Locoregional Breast Cancer Recurrences. Breast Care (Basel). Aug 2015: 10(4): 265–71
• Rajski M, Saaf A, Buess M., 2015, “BMP2 response pattern in human lung fibroblasts predicts outcome in lung adenocarcinomas“,BMC Med Genomics 8:16
• Michael Schlumpf, Claude Fischer, Diana Naehrig, Christoph Rochlitz, Martin Buess “Results of concurrent radio-chemotherapy for the treatment of head and neck squamous cell carcinoma in everyday clinical practice with special reference to early mortality“, 2013, BMC Cancer: 13:610
• Bontognali S, Pless M, Brutsche MH, Fischer C, Rochlitz C, Buess M., “Analysis of the EGFR mutation status in head and neck squamous cell carcinoma before treatment with Gefitinib”, 2013, Onkologie;36(4):161-6
• Martin Buess, 2013, Pazopanib, Kurzbewertung, Internistische Praxis 53 (4) 887-890
• Rajski M, Vogel B, Baty F, Rochlitz C, Buess M., “Global Gene Expression Analysis of the Interaction between Cancer Cells and Osteoblasts to predict Bone Metastasis in Breast Cancer”, 2012, PLoS One 7(1):e29743. Epub 2012 Jan 3
• Martin Buess, 2011, „Metastasiertes Nierenzellkarzinom. Heutige therapeutische Optionen“ Internistische Praxis 51 (4) 787-794
• Rajski M, Zanetti-Dallenbach R, Vogel B, Herrmann R, Rochlitz C, Buess M., “IGF-I induced genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patients”, 2010 BMC Medicine Jan 5;8 (1):1
• Baty F, Facompré M, Kaiser S, Schumacher M, Pless M, Bubendorf L, Savic S, Marrer E, Budach W, Buess M, Kehren J, Tamm M, Brutsche MH. “Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer.” 2010 Am J Respir Crit Care Med. 15;181(2):181-8.
• Martin Buess, Michal Rajski, Brigitte ML Vogel-Durrer, Richard Herrmann and Christoph Rochlitz, “Tumor-Endothelial Interaction links the CD44+/CD24− Phenotype with Poor Prognosis in Early-Stage Breast Cancer”, 2009 Neoplasia 11(10), 987-1002
• Martin Buess, “New therapeutic opportunities in metastatic renal cell carcinoma” Praxis, 2009 98(9) 481-6
• Martin Buess, Dimitry S.A. Nuyten, Trevor Hastie, Torsten Nielsen, Robert Pesich and Patrick O. Brown, “Characterization of heterotypic interaction effects in vitro to deconvolute global gene expression profiles in cancer” , 2007, Genome Biology, 8 (9) R191
• Martin Buess, 2007, „Chemotherapie beim Bronchialkarzinom, Der Patient unter Chemotherapie zwischen Hausarzt und multidisziplinärem Zentrum“ Aktuell Onkologie 2/2007 20-22
• Zeiser R, Nguyen VH, Hou JZ, Beilhack A, Zambricki EA, Buess M, Contag CH, Negrin RS, “Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft versus host disease”, 2007 Blood, 109: 2225-33
• Robert Zeiser, Vu H. Nguyen, Andreas Beilhack, Martin Buess, Stephan Schulz, Jeanette Baker, Christopher H. Contag, and Robert S. Negrin, “Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production”, 2006, Blood, 108:390-399
• Iana Storojeva, Jean-Louis Boulay, Pierluigi Ballabeni, Martin Buess, Luigi  Terracciano, Urban Laffer, Gabriele Mild, Richard Herrmann and Christoph Rochlitz,  “Prognostic and predictive relevance of DNAM-1, SOCS6 and CADH-7 genes on chromosome 18q in colorectal cancer”, 2005, Oncology, 68:246-255
• Martin Buess, Luigi Terraciano, Jürgen Reuter, Pierluigi Ballabeni, Jean-Louis Boulay, Urban Laffer, Urs Metzger, Richard Herrmann and Christoph Rochlitz, “STRAP is a strong predictive maker of adjuvant chemotherapy benefit in colorectal cancer”, 2004, Neoplasia, 6: 813-20
• Martin Buess, Michael Steuerwald, Werner Wegmann and Madeleine Rothen, “ Obstructive jaundice caused by an enteropathy associated T-cell lymphoma in a patient with celiac sprue”, 2004, Journal of Gastroenterology, 39: 1110-1113
• M. Pache, H. Kain, M. Buess, J. Flammer, P. Meyer, 2004, “Primary intraocular lymphoma with unusual clinical presentation and poor outcome“, Klinische Monatsblätter für Augenheilkunde, 221: 401-403
• M. Mayr, O. Giannini, A.Jehle, S. Sadallah, M. Buess, M. Mihatsch, M Trendelenburg, 2004, “Rezidivierende Angioödeme bei Systemischem Lupus Erythematodes (SLE)”, Schweiz Med Forum 4: 1279-81
• P. Welter, M. Buess, 2004, „Supraklavikuläre isolierte Lymphadenopathie“, Schweizerische Rundschau medizinische Praxis, 93 (7): 245-247
• D. Handschin, A. Zeller, W. Wiesner, M. Buess, 2004, „63-jährige Patientin mit rechtsseitigen Unterbauchschmerzen sechs Monate nach Appendektomie“ Schweizerische Rundschau medizinische Praxis, 93: 24 – 26
• Häusermann P, Khanna N, Buess M, Itin PH, Battegay M, Dirnhofer S, Buechner SA, 2004, „Cutaneous Plasmablastic Lymphoma in an HIV-Positive Male: An Unrecognized Cutaneous Manifestation“, Dermatology, 208(3):287-90
• Martin Buess, Luigi Terraciano, Jürgen Reuter, Pierluigi Ballabeni, Jean-Louis Boulay, Urban Laffer, Urs Metzger, Richard Herrmann and Christoph Rochlitz, 2004, “Amplification of SKI is a prognostic marker in early colorectal cancer”, Neoplasia 6 (3): 207-12
• Claudio Gobbi*, Martin Buess*, Alphonse Probst, Stefan Rüegg, Peter Schraml, Richard Hermann, Andreas J. Steck and  Stefan Dirnhofer, 2003, "Enteropathy associated T-cell lymphoma with initial manifestation in the CNS", Neurology, 66:1718-1719, * = contributed equally
• Martin Buess, 2003, „Zellen im Tumorumfeld der Neurofibromatose: unschuldige Zaungäste oder Kollaborateure“, Schweiz Med Forum, 5: 114-115
• Ulrich Certa, Remo Hochstrasser, Hanno Langen, Martin Buess and Christoph Moroni, 1999, "Biosensors in Biomedical Research: Development and Applications of Gene Chips", Chimia, 53: 57-61
• Martin Buess, Oliver Engler, Hans H. Hirsch and Christoph Moroni, 1999 "Search for oncogenic regulators in an autocrine tumor model using differential display PCR: Identification of novel candidate genes including the calcium channel mtrp6", Oncogene, 18: 1487-94
• Martin Buess, Christoph Moroni and Hans H. Hirsch, 1997, "Direct identification of differentially expressed genes by cycle sequencing and cycle labeling using the differential display PCR primers", Nucleic Acids Research, 25, (11): 2233-35

Vortrag über Best Pratices im Claraspital